Morganna Freeman, D.O.
- Medical Oncology
Areas of Expertise
- Merkel Cell Carcinoma
- Squamous Cell Carcinoma
Other Languages Spoken
Medicine is a service and health care is a right.”
Morganna Freeman, D.O., has known since the age of 6 that she wanted to be a doctor and a leader. Her goal is “to reach out to a vulnerable population,” which she does as a foremost authority on melanoma and a vigorous patient advocate for better health care.
A native of San Antonio, Texas, Dr. Freeman received her medical degree from Lake Erie College of Osteopathic Medicine, Bradenton, Florida, followed by her residency at the University of Florida and a fellowship in hematology and oncology at Moffitt Cancer Center in Tampa, Florida. During her training, she helped bring quality medical care to rural clinics in Uganda, Guatemala and Nicaragua and developed her ongoing passion for health care policy.
Dr. Freeman has specialized training in leading-edge immunotherapy treatments for melanoma and is conducting further research into its potential in other skin cancers. She has published numerous peer-reviewed papers and is an honored recipient of advocacy and health policy awards. Dr. Freeman is also a sought-after authority on cancer immunotherapy, appearing frequently across the country in public awareness campaigns.
- 2018-present, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, Medical Director, Affiliate & Community Practices, City of Hope, Duarte, CA
- 2016-2018, Associate Director, Melanoma & Cutaneous Oncology Program, The Angeles Clinic & Research Institute, Los Angeles, CA
- 2009, M.D., Osteopathic, Lake Erie College of Osteopathic Medicine, Bradenton, FL.
- 2013-2016, Hematology & Oncology, Moffitt Cancer Center and University of South Florida, Tampa, FL
- 2012-2013, Internal Medicine, University of Florida, Gainesville, FL
- 2009-2013, Internal Medicine, University of Florida, Gainesville, FL
- 2016, Medical Oncology, American Board of Internal Medicine
- 2016, California Board of Osteopathic Medicine
- 2013, American Board of Internal Medicine
- 2013, Florida Board of Osteopathic Medical Examiners
- Zumsteg Z, Yoshida EJ, Luu M, Freeman M, Essner R, Gharavi N, Shiao S, Mallen-St Clair J, Hamid O, Ho A. “The Association Between Facility Characteristics and Survival in Patients with Merkel Cell Carcinoma” (accepted to Journal of American Academy of Dermatology).
- Freeman M, Moreira R, Hamid O, Ott PA. Principles of Combination Immunotherapies (Book Chapter). Textbook of Cancer Immunotherapy Principles and Practice, Society for Immunotherapy of Cancer.
- Knepper C, Freeman M, Gibney G, McLeod HL, Russell JS. Case Report of a Clinical Response to Pazopanib in a Patient with KDR-Mutated Metastatic Basal Cell Carcinoma. JAMA Dermatol. 2017;153(6):607–609. (PMID: 28384659).
- Bollin K, Freeman M. Advances in clinical immunotherapy of melanoma. Journal of Translational Cancer Research. 2017; 6(1): 3-16.
- Lowry P, Freeman M, Russell JS. Oncologic Nursing Management of a Rare Skin Cancer: Advanced Merkel Cell Carcinoma. Oncol Nurs Forum. 2016 Nov 1;43(6):680-683 (PMID: 27768129).
- Freeman M. Tanning Bed Legislation in 2016: Are We Any Closer to Closing the Lid? J Cancer Prev Curr Res 5(6):00183.
- Freeman M, Carvajal RD, Faries M, Hamid O. Cutaneous Malignancies: Unusual Melanomas (Book Chapter). Textbook of Uncommon Cancer, 5th Edition.
- Freeman M. Immunotherapy for Malignant Melanoma: Current Perspectives and Future Directions (Book Chapter). Textbook of Management of Malignant Melanoma, smgebooks.com.
- Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Correlation with Outcomes. Clinical Cancer Research (PMID: 26446948).
- Freeman-Keller M, Goldman J, Gray JG. (2015) Vaccine Immunotherapy in Lung Cancer: Clinical Experience and Future Directions. Pharmacology & Therapeutics 153: 1–9. (PMID: 25989231).
- Freeman-Keller M, Weber JS. (2015) Nivolumab in resected and unresectable melanoma: Immune-related adverse events and association with survival outcomes. ASCO Annual Meeting Proceedings 33(15): Suppl p. 9028.
- Freeman-Keller M, Weber JS. (2015) Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential. Therapeutic Advances in Medical Oncology 7(1):12-21. (PMID 25553080).
- American Association for Cancer Research
- American Cancer Society Cancer Action Network
- American College of Physicians
- American Medical Association
- American Society of Clinical Oncology
- American Society of Hematology
- ASCO Conquer Cancer Foundation
- Melanoma Research Alliance
- Melanoma Research Foundation
- National Association of Professional Women
- National Comprehensive Cancer Network
- Society for Immunotherapy of Cancer
- Society for Melanoma Research
- Society for Translational Oncology
- 2018, Melanoma Research Foundation Humanitarian Award
- 2017, Top Doctors For Women, Los Angeles Magazine
- 2017-2018, Rising Star, Super Doctors of Southern California, Los Angeles Magazine
- 2015-2017, ASCO Advocacy Champion